Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer

Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer

Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive <i>EGFR</i>-mutant non-small cell lung cancer, Published online: 30 November 2017; doi:10.1038/bjc.2017.394

Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer

from Cancer via ola Kala on Inoreader http://ift.tt/2irtg65
via IFTTT